NORD comments on Reauthorization of the Prescription Drug User Fee Act
Published: Aug 21, 2020
Tagged in: User Fee Act, Advancing Rare Disease Research and Regulatory Science
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD comments on Reauthorization of the Prescription Drug User Fee Act
Published: Aug 21, 2020
Tagged in: User Fee Act, Advancing Rare Disease Research and Regulatory Science
NORD submits comments to FDA on Request for Information on Rare Disease Clinical Trial Networks
Published: Jul 31, 2020
Tagged in: Advancing Rare Disease Research and Regulatory Science, Rare Disease Clinical Trials, Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP)
NORD submits comments on FDA Draft Guidance on Interpreting Sameness for Gene Therapy Products Under the Orphan Drug Regulations
Published: Jul 28, 2020
Tagged in: Gene Therapies, Advancing Rare Disease Research and Regulatory Science, Orphan Drug Act
NORD letter in support of Connecticut House Bill 5297, an act requiring continuing medical education in screening for rare gastrointestinal cancers
Published: Apr 18, 2018
Tagged in: Advancing Rare Disease Research and Regulatory Science
Coalition letter to Congress regarding medical research within the fiscal year 2019 National Defense Authorization Act
Published: Feb 27, 2018
Tagged in: Advancing Rare Disease Research and Regulatory Science